Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capecitabine plus Irinotecan Chemoradiotherapy in Rectal Cancer
NCT00506623Phase 2Unknown
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Jul 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan in rectal cancer, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Pathologic Complete Response. Status: unknown.
02
Drugs
irinotecan
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT00506623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00506623.